About the Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. Session
Genetic testing and biomarkers are reshaping cancer care through risk stratification and precision medicine. Advances in genetic profiling enable the identification of hereditary cancer syndromes, guiding preventive measures and early interventions. Biomarkers such as PD-L1, HER2, and EGFR are integral to targeted therapies, improving efficacy and reducing side effects. Liquid biopsy and genomic sequencing provide real-time monitoring of cancer progression and treatment response. Research focuses on discovering novel biomarkers and expanding the utility of genetic testing, making cancer care more individualized and effective.
Topics Covered in Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy.
Germline Risk Variants
Multigene Panel Testing
Polygenic Risk Scores
Tumor Genomic Profiling
Predictive Biomarkers
Companion Diagnostics
Related Scientific Sessions at CIOC 2027
Why Attend the Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. Conference 2027 — FAQs
What is the Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. track at CIOC 2027?
The Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy.. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. sessions?
Cancer researchers and clinicians, educators and students with an interest in Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. are all welcome — whether presenting or attending.
Can I present my research in the Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy. track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.